Countdown to ASH 2024: What to Expect in Breakthroughs in Hematology-Oncology
The 66th American Society of Hematology (ASH) Annual Meeting is almost here, from December 7-10 in San Diego and online! This year’s gathering will be packed with groundbreaking developments in hematology and oncology. Here’s a glimpse into some of the highly anticipated presentations from industry frontrunners—just a few among hundreds of exciting advancements that will be showcased:
Ascentage Pharma
Announced that multiple studies of its investigational drug candidate, olverembatinib (HQP1351), have been selected for presentations, including an Oral Report, at ASH 2024.
Link to announcement: https://www.ascentage.com/ash-2024-studies-of-olverembatinib-selected-for-presentations-including-an-oral-report-for-the-seventh-consecutive-year/?utm_source=chatgpt.com
AstraZeneca
Showcasing data across its hematology portfolio and pipeline, with a total of 57 abstracts featuring 13 approved and potential new medicines at ASH 2024.
Link to announcement: https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-at-ash-2024.html
Advancements in engineered B cell therapies with potential impact on a wide range of hematologic conditions.
Link to announcement: https://www.businesswire.com/news/home/20241105892483/en/Be-Biopharma-Announces-Upcoming-Presentation-at-the-66th-American-Society-of-Hematology-ASH-Annual-Meeting
Bristol Myers Squibb
Presenting over 90 data disclosures, including 18 oral presentations, across company-sponsored studies, investigator-sponsored studies, and collaborations from its hematology and cell therapy research programs.
Bluebird bio
Updates on LentiGlobin, a promising therapy for beta thalassemia, including data for sickle cell disease patients.
Link to announcement: https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-present-additional-long-term-follow-data-gene
Cartesian Therapeutics
Presenting data on the safety and tolerability of Descartes-08, an mRNA CAR-T therapy targeting BCMA, designed for autoimmune diseases and multiple myeloma, offering innovative advantages like outpatient administration without preconditioning chemotherapy.
Link to announcement: https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-presentation-upcoming-66th-ash
CellCentric
Presenting new safety and efficacy data from the Phase II trial of inobrodib, a novel oral p300/CBP inhibitor for relapsed refractory multiple myeloma, highlighting its potential in combination with pomalidomide and dexamethasone.
Link to announcement: https://www.cellcentric.com/press-release/cellcentric-to-share-latest-inobrodib-phase-ii-data-oral-presentation-at-ash-2024/
Century Therapeutics
Presenting preclinical data across iNK, γδ iT, and αβ iT cell therapy pipelines for oncology and autoimmune diseases.
Link to announcement: https://investors.centurytx.com/news-releases/news-release-details/century-therapeutics-announces-upcoming-poster-presentations
Cogent Biosciences
Sharing data from the APEX and SUMMIT Phase 2 trials of bezuclastinib, a selective KIT D816V tyrosine kinase inhibitor, highlighting its potential in both advanced and nonadvanced systemic mastocytosis.
Link to announcement: https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-bezuclastinib-presentations-66th
Disc Medicine
Sharing data from the Phase 1b trial of DISC-0974 in myelofibrosis-related anemia, highlighting its potential as a novel treatment. Additional findings from the AURORA and BEACON trials of bitopertin in erythropoietic protoporphyria will also be presented.
Link to announcement: https://www.globenewswire.com/fr/news-release/2024/11/05/2974975/0/en/Disc-Medicine-Announces-Multiple-Presentations-Across-Portfolio-at-the-66th-American-Society-of-Hematology-ASH-Annual-Meeting.html
ECOG-ACRIN Cancer Research Group
Sharing data from the ECOG-ACRIN EA4151 Phase 3 trial, examining the role of autologous hematopoietic cell transplantation in mantle cell lymphoma patients with undetectable minimal residual disease. Additional findings from the PrE0905 and EA4181 studies demonstrate promising results in AML and mantle cell lymphoma, respectively.
Link to announcement: https://ecog-acrin.org/press-release-ecog-acrin-and-precog-announce-multiple-presentations-at-ash-2024/
Eli Lilly and Company
Presenting results from the Phase 3 BRUIN CLL-321 study, evaluating Jaypirca® (pirtobrutinib) against standard therapies in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with BTK inhibitors.
Link to announcement: https://investor.lilly.com/news-releases/news-release-details/lilly-announces-details-presentations-2024-american-society-0
Genmab A/S
Showcasing over 20 abstracts on epcoritamab-bysp (EPKINLY®), including data from the EPCORE NHL-1 trial in relapsed or refractory large B-cell lymphoma (LBCL), highlighting its potential across various B-cell malignancies.
Link to announcement: https://ir.genmab.com/news-releases/news-release-details/genmab-showcase-strength-and-breadth-comprehensive-epcoritamab
Geron Corporation
Presenting four abstracts on imetelstat, a telomerase inhibitor for myelofibrosis, with Phase 2/3 updates.
IN8bio
Sharing data from the INB-100 pilot study, evaluating gamma-delta T-cell therapy following haploidentical stem-cell transplantation, highlighting the potential of innovative gamma-delta T-cell-based immunotherapies in treating AML.
Link to announcement: https://investors.in8bio.com/news-releases/news-release-details/in8bio-announces-upcoming-presentation-2024-american-society/
Lyell Immunopharma
Introducing early data on IMPT-314, an FDA Fast Track-designated CAR T-cell therapy targeting CD19/CD20 for aggressive B-cell lymphomas.
Link to announcement: https://ir.lyell.com/news-releases/news-release-details/lyell-announces-presentation-initial-clinical-data-phase-1-2
Nurix Therapeutics
Presenting data from the NX-5948 Phase 1a/b study, highlighting the efficacy and safety of BTK degradation in patients with relapsed/refractory CLL. Additional findings from the NX-2127 program demonstrate improved T-cell functionality. Press Release
Link to announcement: https://www.biospace.com/press-releases/nurix-therapeutics-announces-presentations-at-the-66th-american-society-of-hematology-ash-annual-meeting
Rgenta Therapeutics
Updates on small molecules targeting RNA regulation for cancer therapies.
Link to announcement: https://www.prnewswire.com/news-releases/rgenta-therapeutics-announces-presentation-at-the-66th-american-society-of-hematology-ash-annual-meeting-302295935.html
Rigel Pharmaceuticals
Announced six poster presentations highlighting data from their commercial and clinical-stage hematology-oncology portfolio, including initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in lower-risk myelodysplastic syndrome (LR-MDS), and additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Link to announcement: https://www.rigel.com/investors/news-events/press-releases/detail/400/rigel-announces-six-poster-presentations-at-the-66th
Umoja Biopharma
Announced two oral presentations and one poster presentation, including data on their VivoVec™ in vivo gene delivery technology and the generation of B Cell depleting CAR T cell therapies for the treatment of autoimmune diseases in non-human primates.
Link to announcement: https://www.umoja-biopharma.com/news/umoja-biopharma-announces-oral-and-poster-presentations-at-the-66th-american-society-of-hematology-annual-meeting/
Vittoria Biotherapeutics
Highlighting advancements in their Senza5™ platform, focused on enhancing T-cell functionality through CD5 modulation, with potential breakthroughs in cancer and immune disease therapies.
Link to announcement: https://www.morningstar.com/news/globe-newswire/9278737/vittoria-biotherapeutics-announces-oral-and-poster-presentations-at-the-66th-american-society-of-hematology-ash-annual-meeting
Don’t miss out on these and hundreds of other trailblazing advancements! ASH 2024 promises invaluable insights into the therapies shaping the future of hematology-oncology.
